Dipyrone enhances intracellular accumulation and cytotoxicity of adriamycin in human chronic myeloid leukemia cells.
The cytotoxicity induced by dipyrone alone, or in combination with adriamycin (ADR) was studied in human chronic myeloid leukemia (CML) cells. The inhibition of 3H-thymidine incorporation into DNA was taken as a measure of cytotoxicity. While dipyrone alone indicated marginal inhibition, its combination with ADR demonstrated a potentiating effect (p less than 0.001), which was found to be irreversible. The enhanced cytotoxicity of the combination was a result of an increased drug accumulation as studied by the uptake of 14C-adriamycin. Observations indicate that dipyrone can be used to enhance the cytotoxicity of ADR in human CML patients.
Chitnis
M P
MP
Cellular Chemotherapy Unit, Tata Memorial Center, Parel, Bombay, India.
Kamath
N S
NS
Parekh
H K
HK
Advani
S H
SH
D002470:Cell Survival / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004177:Dipyrone / Q000494:pharmacology*; D004317:Doxorubicin / Q000378:metabolism / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
D004177:Dipyrone; D004317:Doxorubicin; D004247:DNA; D013936:Thymidine